A retrospective analysis of Escherichia coli isolates collected from community-acquired urinary tract infections (UTIs) in the United States for the years 2010-2022 was performed. The data originated from accessing the SENTRY Antimicrobial Surveillance Program, which is a global monitoring program that has been ongoing since 1997 with a purpose of tracking and reporting susceptibility of clinical isolates collected from various infection sources. Isolates meeting the Centers for Disease Control and Prevention definition for community-acquired UTI were tested for antimicrobial susceptibility against 17 antimicrobial agents using broth microdilution methodology specified by the Clinical & Laboratory Standards Institute (CLSI) guidelines. Isolates were interpreted as susceptible, intermediate, or resistant as appropriate using CLSI and European Committee on Antimicrobial Susceptibility Testing breakpoints and characterized for extended-spectrum β-lactamase and multidrug-resistant phenotypes. The percentage of isolates susceptible to the oral agents amoxicillin-clavulanate, trimethoprim-sulfamethoxazole, and fluoroquinolones was 70%-85% throughout the study period, which crosses the acceptable threshold of 80% for empiric use of trimethoprim-sulfamethoxazole per the 2010 Infectious Disease Society of America guidelines. Higher susceptibility (>90%) was observed for all agents administered via intravenous or intramuscular route. Variation in susceptibility profiles was observed by census region with the highest resistant rates commonly found in the Middle Atlantic. These data highlight the need for more oral options when treating community-acquired UTIs.
Arends et al. (Fri,) studied this question.